|
|
 |
October 30, 2008 |
Now Available:
Watch video podcasts of press conference footage from ACR 2008
CME Meetings:
Musculoskeletal Report provides cutting-edge scientific updates through biweekly and special edition newsletters, in-depth interviews, and on-location coverage of medical meetings.
With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.
ACR 2008: Visit MSK Report's dedicated ACR 2008 page
for complete coverage of the American College of Rheumatology's Annual Scientific Meeting, including press conference videos and interviews with presenters.
ACR 2008: Denosumab Bests Alendronate for Increasing Bone Mass
One year of denosumab was more likely to produce a 3% gain in hip or spine bone mass than one year of alendronate...
ACR 2008: Old Malaria Drug Reduces Diabetes Risk in RA, Protects Kidneys in Lupus
The inexpensive old drug hydroxychloroquine (HCQ) shows remarkable protective ability against diabetes in patients with rheumatoid arthritis and against renal disease in patients with lupus...
ACR 2008: Abatacept Helps Kids With Arthritis Stay in School
Children with juvenile idiopathic arthritis treated with abatacept (Orencia) missed fewer school days than those who received placebo...
ACR 2008: Lupus Kidney Failure Rate Skyrocketing in Black Women
For the first time, African Americans, who comprise 13% of the US population, account for nearly half of all cases of kidney failure due to systemic lupus erythematosus (SLE). Most affected are black women, whose risk of end-stage renal disease due to lupus nephritis is nearly 10 times that of white women...
Consumer News: Rheumatoid Arthritis Rising in Women
The incidence of rheumatoid arthritis among women fell during the second half of the 20th century, but is now on the rise in the US...
BioPharm Business: Merck, Japan Tobacco in Osteoporosis Drug Deal
Merck and Japan Tobacco announced a worldwide licensing agreement to develop and commercialize JTT-305, an investigational oral osteoanabolic agent for the treatment of osteoporosis...